SpayVac-for-Wildlife and BioVaxys Technology Corp. announced today positive results from their collaborative research project.

According to a release, a single dose of SpayVac-for-Wildlife’s immunocontraceptive vaccine called SpayVac pZP reduced fertility to 11% in vaccinated deer compared to a fertility rate of 86% in control animals.

“These results are another example of replication and proof of concept that SpayVac pZP vaccine is very effective,” SpayVac VP of Operations Dr. Mark Fraker said in a statement. “It replicates other results we’ve seen in deer and other species. Therefore, we continue developing indications and other vaccines for markets where SpayVac might offer an appealing alternative to spaying or short-acting immunocontraceptives in farm-production animals and companion animals.”

The study, which lasted one year, was done with 47 free-ranging red deer. The company is currently conducting trials with feral horses, farmed trout, Asian elephants and other species.

SpayVac-for-Wildlife has also initiated the submission process to secure regulatory approval for SpayVac.